The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://marleyllhi695350.blogofchange.com/39715736/glp-3-retatrutide-a-comparative-analysis